Idera Pharmaceuticals, Inc. Announces Agreement With Abbott Laboratories To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-Cell Lymphoma
Published: May 08, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced today that it has entered into an agreement with Abbott, the global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera’s clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.
Help employers find you! Check out all the jobs and post your resume.